Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

Trial Details

NCT ID

NCT07094685

Phase

PHASE2

Sponsor

University of Michigan Rogel Cancer Center

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Computed Tomography
Ivonescimab
Magnetic Resonance Imaging
Positron Emission Tomography

Locations (sample)

Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

At least 18 years of age
PD-L1 combined positive score (CPS) \>= 1
Histologically documented advanced stage mucosal HNSCC (stage II-IV), for which surgery would be recommended in routine clinical practice
Primary tumor is amenable to fresh biopsy or availability of archival fresh frozen primary tissue

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →